Biosimilars 2021 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
JANUARY 11, 2022
For example, Amgen recently announced that it has Phase 3 studies under way to support interchangeability status for its adalimumab and ustekinumab biosimilars, Amjevita ™ and ABP 654, respectively. Introduction. Yet, given fewer FDA approvals in 2020 and 2021, this year saw the lowest number of commercial launches since 2017. Conclusion.
Let's personalize your content